Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA

Go back to Arrowhead reports early data for dual-gene RNAi therapy ARO-DIMER-PA

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

September 15, 2026 7:30 AM EDT

- ARO-DIMER-PA achieved deep and durable silencing of two genes with a single RNAi molecule

- Mean maximal single dose reductions in serum PCSK9 of 72% and APOC3 of 88%

- Clinical validation further demonstrates Arrowheads position as the leading innovator in siRNA therapies -

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals,... More